Dermatol. praxi. 2023;17(2):97-99 | DOI: 10.36290/der.2023.017

Severe form of atopic dermatitis - Successful treatment with abrocitinib

MUDr. Michaela Chmelíková, MUDr. Milena Tánczosová, Ph.D.
Dermatovenerologická klinika 3. LF UK a FNKV, Praha

Atopic dermatitis is a chronic inflammatory skin disease that affects both children and adults. It is characterized by intense itching, redness, and scaling of the skin. The pathogenesis of atopic dermatitis involves complex interactions between genetic, immunological, and environmental factors. JAK inhibitors are a new class of drugs that target the Janus kinase (JAK) signaling pathway, which plays a key role in the pathogenesis of atopic dermatitis. JAK inhibitors have been shown to effectively reduce inflammation in a variety of inflammatory diseases, including atopic dermatitis.

Keywords: atopic dermatitis, systemic treatment, abrocitinib, mechanism of action.

Accepted: June 1, 2023; Published: June 7, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chmelíková M, Tánczosová M. Severe form of atopic dermatitis - Successful treatment with abrocitinib. Dermatol. praxi. 2023;17(2):97-99. doi: 10.36290/der.2023.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66:8-16. Go to original source...
    2. Tánczosová M. Závažné formy atopické dermatitidy - aktuální stav, možnosti a perspektivy terapie v České republice. Farmakoterapeutická revue. 2020;5(3):256-262.
    3. Ciclosporin - souhrn údajů o přípravku [Internet]. Available from: www.sukl.cz.
    4. Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int. J. Mol. Sci. 2021;22:4130. Go to original source... Go to PubMed...
    5. Dupixent - souhrn údajů o přípravku [Internet]. Available from: www.sukl.cz.
    6. Nakashima, Chisa et al. "Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors." Allergology international:official journal of the Japanese Society of Allergology. 2022;71(1):40-46. Go to original source...
    7. Samuel C, Cornman H, Kambala A, Kwatra SG. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Dermatol Ther (Heidelb). 2023;13(3):729-749. Go to original source... Go to PubMed...
    8. Cibinqo - souhrn údajů o přípravku [Internet]. Available from: www.sukl.cz.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.